Westyn Branch-Elliman, MD, MMSc

Adjunct Instructor, Medicine

Westyn Branch-Elliman

Biography

I am a physician investigator who focuses on optimizing healthcare resource utilization and expanding infection prevention programs beyond traditional boundaries. My research projects include epidemiologic and economic evaluations of postpartum breast infections, comparative and cost-effectiveness evaluations of preventions designed to reduce healthcare-associated infections (HAI), and development of novel electronic tools for improved HAI detection. The majority of my time is dedicated to clinical research. I also see patients and teach medical students, residents and infectious diseases fellows. In my previous role as the Medical Director of Infection Prevention at the Eastern Colorado VA Healthcare System, I dedicated significant effort to administrative responsibilities, including healthcare epidemiology and antimicrobial stewardship.

Other Positions

  • VA Boston Healthcare System

Education

  • Northwestern University School of Medicine, MD
  • Harvard Medical School, MMS/MMSc
  • University of California, Berkeley, BA

Publications

  • Published on 7/1/2022

    Jones M, Khader K, Branch-Elliman W. Estimated Impact of the US COVID-19 Vaccination Campaign-Getting to 94% of Deaths Prevented. JAMA Netw Open. 2022 Jul 01; 5(7):e2220391. PMID: 35793090.

    Read at: PubMed
  • Published on 5/23/2022

    La J, Wu JT, Branch-Elliman W, Huhmann L, Han SS, Brophy MT, Do NV, Lin AY, Fillmore NR, Munshi NC. Increased COVID-19 Breakthrough Infection Risk in Patients with Plasma Cell Disorders. Blood. 2022 May 23. PMID: 35605185.

    Read at: PubMed
  • Published on 5/23/2022

    Corrigan JK, La J, Fillmore NR, Do NV, Brophy M, Doron S, Monach PA, Branch-Elliman W. Coronavirus disease 2019 (COVID-19) hospitalization metrics that do not account for disease severity underestimate protection provided by severe acute respiratory coronavirus virus 2 (SARS-CoV-2) vaccination and boosting: A retrospective cohort study. Infect Control Hosp Epidemiol. 2022 May 23; 1-3. PMID: 35599374.

    Read at: PubMed
  • Published on 5/19/2022

    Wang S, Quan L, Ding M, Kang JH, Koenen KC, Kubzansky LD, Branch-Elliman W, Chavarro JE, Roberts AL. Depression, worry, and loneliness are associated with subsequent risk of hospitalization for COVID-19: a prospective study. Psychol Med. 2022 May 19; 1-10. PMID: 35586906.

    Read at: PubMed
  • Published on 5/1/2022

    Schechter-Perkins EM, Doron S, Johnston R, Hay J, Berlin D, Ciaranello A, Nelson SB, Gormley JM, Smole SC, Brown CM, Madoff LC, Branch-Elliman W. A Test-to-Stay Modified Quarantine Program for COVID-19 in Schools. Pediatrics. 2022 May 01; 149(5). PMID: 35132435.

    Read at: PubMed
  • Published on 4/25/2022

    Branch-Elliman W, Elwy AR, Lamkin RL, Shin M, Engle RL, Colborn K, Rove J, Pendergast J, Hederstedt K, Hawn M, Mull HJ. Assessing the sustainability of compliance with surgical site infection prophylaxis after discontinuation of mandatory active reporting: study protocol. Implement Sci Commun. 2022 Apr 25; 3(1):47. PMID: 35468871.

    Read at: PubMed
  • Published on 4/11/2022

    Belyayev LA, Foroushani SM, Wiener DC, Branch-Elliman W, Marshall MB, Khalil HA. Bronchopleural fistula due to cavitary pneumonia after SARS-CoV-2 infection treated with open thoracostomy. J Surg Case Rep. 2022 Apr; 2022(4):rjac076. PMID: 35422997.

    Read at: PubMed
  • Published on 3/23/2022

    van den Berg P, Schechter-Perkins EM, Jack RS, Epshtein I, Nelson R, Oster E, Branch-Elliman W. Corrigendum to: Effectiveness of 3 Versus 6 ft of Physical Distancing for Controlling Spread of Coronavirus Disease 2019 Among Primary and Secondary Students and Staff: A Retrospective, Statewide Cohort Study. Clin Infect Dis. 2022 Mar 23; 74(6):1127-1129. PMID: 35170734.

    Read at: PubMed
  • Published on 3/7/2022

    Oster E, Schechter-Perkins EM, Branch-Elliman W. Reply to Klein and Harris. Clin Infect Dis. 2022 Mar 07. PMID: 35253850.

    Read at: PubMed
  • Published on 2/25/2022

    Branch-Elliman W, Ferguson R, Doros G, Woods P, Leatherman S, Strymish J, Datta R, Goswami R, Jankowich MD, Shah NR, Taylor TH, Page ST, Schiller SJ, Shannon C, Hau C, Flynn M, Holmberg E, Visnaw K, Dhond R, Brophy M, Monach PA. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLoS One. 2022; 17(2):e0263591. PMID: 35213547.

    Read at: PubMed

View 71 more publications: View full profile at BUMC

View all profiles